• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.

作者信息

Minson Adrian, Douglas Genevieve, Bilmon Ian, Grigg Andrew

机构信息

Department of Haematology, Austin Hospital, Heidelberg, Vic, Australia.

Department of Haematology, Westmead Hospital, Westmead, NSW, Australia.

出版信息

Br J Haematol. 2019 Mar;184(5):840-844. doi: 10.1111/bjh.15186. Epub 2018 Mar 13.

DOI:10.1111/bjh.15186
PMID:29532918
Abstract
摘要

相似文献

1
Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.异基因干细胞移植后伴有活动性移植物抗宿主病的复发难治性霍奇金淋巴瘤的低剂量程序性死亡受体1抑制治疗
Br J Haematol. 2019 Mar;184(5):840-844. doi: 10.1111/bjh.15186. Epub 2018 Mar 13.
2
Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.肿瘤消退与类固醇难治性移植物抗宿主病同时出现，凸显了异基因造血干细胞移植后程序性死亡蛋白1阻断治疗的缺陷。
Bone Marrow Transplant. 2017 May;52(5):759-761. doi: 10.1038/bmt.2016.346. Epub 2017 Jan 9.
3
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.异基因造血细胞移植后复发淋巴瘤的程序性死亡受体-1阻断治疗：缓解率高但移植物抗宿主病频繁。
Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.
4
Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.异基因造血干细胞移植后发生类似于经典型霍奇金淋巴瘤的移植后淋巴组织增生性疾病，成功接受纳武利尤单抗治疗：一例报告。
J Oncol Pharm Pract. 2021 Mar;27(2):509-512. doi: 10.1177/1078155220946462. Epub 2020 Aug 6.
5
Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.复发性霍奇金淋巴瘤的治疗方法：包括免疫疗法在内的移植和非移植方法。
Hematology Am Soc Hematol Educ Program. 2005:245-51. doi: 10.1182/asheducation-2005.1.245.
6
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.霍奇金淋巴瘤患者接受高剂量化疗和自体干细胞移植失败后的生存分析。
Ann Hematol. 2018 Jul;97(7):1229-1240. doi: 10.1007/s00277-018-3283-z. Epub 2018 Feb 26.
7
Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.一名接受异基因非亲属移植后复发的霍奇金淋巴瘤患者使用纳武单抗治疗后发生耐药性移植物抗宿主病
Klin Onkol. 2019 Winter;32(1):66-69. doi: 10.14735/amko2019.
8
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.PD-1 阻断可诱导异基因造血干细胞移植后复发的经典霍奇金淋巴瘤缓解。
J Immunother Cancer. 2017 Feb 21;5:11. doi: 10.1186/s40425-017-0211-z. eCollection 2017.
9
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.阿仑单抗-大剂量化疗联合自体骨髓移植预处理用于复发/难治性霍奇金淋巴瘤的异基因造血干细胞移植：一项单中心分析
J Cancer Res Clin Oncol. 2016 Jun;142(6):1307-14. doi: 10.1007/s00432-016-2134-3. Epub 2016 Feb 26.
10
Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.联合异环磷酰胺、依托泊苷和奥沙利铂化疗治疗 ABVD/EBVP 后首次复发或难治性霍奇金淋巴瘤的低毒方案：一项针对 34 例患者的前瞻性单中心研究。
Br J Haematol. 2011 Apr;153(2):191-8. doi: 10.1111/j.1365-2141.2011.08594.x. Epub 2011 Mar 8.

引用本文的文献

1
Low-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis.低剂量程序性死亡蛋白1抑制疗法用于复发/难治性经典型霍奇金淋巴瘤：系统评价与荟萃分析
Invest New Drugs. 2025 Jul 21. doi: 10.1007/s10637-025-01565-0.
2
Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.免疫检查点抑制剂的给药方案：降低剂量、减少频次、缩短疗程的尝试。
Front Oncol. 2022 Jun 20;12:906251. doi: 10.3389/fonc.2022.906251. eCollection 2022.
3
Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors.
造血干细胞移植后复发：检查点抑制剂的作用
Health Sci Rep. 2022 Mar 8;5(2):e536. doi: 10.1002/hsr2.536. eCollection 2022 Mar.
4
Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.病例报告：同种异体造血干细胞移植后伴 RUNX1-RUNX1T1 分子复发的急性髓系白血病患者采用低剂量 PD-1 阻断和阿扎胞苷进行抢先治疗。
Front Immunol. 2022 Feb 2;13:810284. doi: 10.3389/fimmu.2022.810284. eCollection 2022.
5
Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review.免疫检查点抑制剂相关的移植物抗宿主病：一项药物警戒研究与系统文献综述
Front Pharmacol. 2021 Feb 5;11:619649. doi: 10.3389/fphar.2020.619649. eCollection 2020.
6
[A clinical study of IGEV regimen in the treatment of relapsed and refractory Hodgkin lymphoma].IGEV方案治疗复发难治性霍奇金淋巴瘤的临床研究
Zhonghua Xue Ye Xue Za Zhi. 2018 Aug 14;39(8):688-690. doi: 10.3760/cma.j.issn.0253-2727.2018.08.017.